VirTus Respiratory Research Supports Development of Apollo Therapeutics’ APL-10456 from Preclinical Proof of Concept to Positive Phase 1 Data

Also Read

• Canadian Businesses Dig In as New U.S. Tariffs Endanger Jobs
• Massive La Tomatina Tomato Fight Draws Thousands to Spain’s Buñol
• Trump’s Korean Gambit Highlights Evolving East Asian Dynamics
• Biotech Stocks At 52-Week Highs – GENB +15%, BDSX +10%, CDNA +6%, CPIX +10%, CRDL +7%